MedTrace Logo

The Effect of Amiloride and Spironolactone in Healthy Persons

NCT00857909 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2011-07-08

No results posted yet for this study

Summary

This study will investigate whether retaining potassium in the body will lead to changes in blood pressure and changes in blood and urine samples.

Conditions

Interventions

DRUG

Amiloride

1 tablet twice a day

DRUG

Spironolactone

1 tablet twice a day

DRUG

Placebo

Placebo

DRUG

Placebo and spironolactone

5mg twice daily

DRUG

Spironolactone

25mg twice daily

Sponsors & Collaborators

  • Regional Hospital Holstebro

    lead OTHER

Principal Investigators

  • Erling B Pedersen, Prof · Regional Hospital Holstebro

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00857909 on ClinicalTrials.gov